Opinion

Thor Halfdanarson: The risk of recurrence following resection of pNETs

Thor Halfdanarson/mayoclinic.org

Nov 1, 2024, 12:08

Thor Halfdanarson: The risk of recurrence following resection of pNETs

Thor Halfdanarson, Vice President at the North American Neuroendocrine Tumor Society, shared on X:

“This is going to be a favorite paper in the clinic when counseling patients on risk of recurrence following resection of pNETs. Node negativity and absence of lymphovascular invasion predict a very favorable outcome and low recurrence risk.”

Thor Halfdanarson

Incidence and Prognostic Implications of Lymphovascular Invasion in Node-Negative Pancreatic Neuroendocrine Tumors: Results From the US Neuroendocrine Study Group

Authors: Kota Sahara, Diamantis I. Tsilimigras, Yuki Homma, Jun Kawashima, Shishir K. Maithel, Flavio Rocha, Sharon Weber, Ryan Fields, Kamran Idrees, George A. Poultsides, Cliff Cho, Itaru Endo, Timothy M. Pawlik

Thor Halfdanarson

More posts featuring Thor Halfdanarson.

cancer Cliff Cho Diamantis I. Tsilimigras Flavio Rocha George A. Poultsides Itaru Endo Jun Kawashima Kamran Idrees Kota Sahara OncoDaily oncoology Ryan Fields Sharon Weber Shishir K. Maithel Thor Halfdanarson Timothy M. Pawlik Yuki Homma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute